Skip to main content

1 Result(s)

within Philipp Mann MD Remove this filter

and

  1. Article

    Open Access

    Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

    We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein...

    Peter G. Kremsner, Philipp Mann MD, Arne Kroidl… in Wiener klinische Wochenschrift (2021)

    Download PDF (514 KB) View Article